Overall, 13 out of 250 Chinese patients with RCC in the OrigiMed2020 cohort had TFE3 translocations, while only 7 out of 525 White patients with RCC in TCGA cohort had TFE3 translocations (5.2% vs 1.3%; OR: 4.1, 95% CI: 1.5-12.2, P = .003; Fig. 2D). This evidence concerns the gene TFE3 and renal cell carcinoma.